TNFSF10 and neoplasm: In order to investigate TRAIL sensitivity and resistance in GBM, a panel of three GBM cell lines, consisting of two commercially available lines, A172 and U87 and a cell line derived from a primary GBM tumour, MZ-294, were treated with TRAIL for 24, 48 and 72 h (Fig 1a).